Published in Contemp Clin Trials on August 12, 2008
Telephone versus internet administration of self-report measures of social anxiety, depressive symptoms, and insomnia: psychometric evaluation of a method to reduce the impact of missing data. J Med Internet Res (2013) 0.86
Feasibility study of a clinically-integrated randomized trial of modifications to radical prostatectomy. Trials (2012) 0.80
Lessons learned from the conduct of a multisite cluster randomized practical trial of decision aids in rural and suburban primary care practices. Trials (2013) 0.77
Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol (1967) 22.39
Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA (2002) 15.53
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry (2000) 7.31
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry (1993) 4.98
Comparability of telephone and face-to-face interviews in assessing axis I and II disorders. Am J Psychiatry (1997) 3.79
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Achieving a 96.6 percent follow-up rate in a longitudinal study of drug abusers. Drug Alcohol Depend (1996) 2.76
Telephone versus in-person interviews for alcohol use: results of the 2000 National Alcohol Survey. Drug Alcohol Depend (2003) 2.36
Telephone assessment of depression severity. J Psychiatr Res (1994) 2.23
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry (2003) 2.03
Perceived barriers to mental health service utilization in the United States, Ontario, and the Netherlands. Psychiatr Serv (2007) 1.82
Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry (2004) 1.75
Agreement between face-to-face and telephone-administered versions of the depression section of the NIMH Diagnostic Interview Schedule. J Psychiatr Res (1988) 1.71
Obtaining follow-up interviews for treatment evaluation. J Subst Abuse Treat (1995) 1.39
Comparison of mail and telephone in assessing patient experiences in receiving care from medical group practices. Eval Health Prof (2005) 1.36
Assessing inner-city patients' hospital experiences. A controlled trial of telephone interviews versus mailed surveys. Med Care (1997) 1.33
Recruitment and retention of homeless mentally ill participants in research. J Consult Clin Psychol (1996) 1.33
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
Assessing mental health in primary care research using standardized scales: can it be carried out over the telephone? Psychol Med (2004) 1.24
Utility of telephone assessments in an older adult population. Psychol Aging (2007) 1.13
Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv (2006) 1.12
Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. J Psychiatr Res (2006) 1.11
The Enhancing Recovery in Coronary Heart Disease Trial (ENRICHD): strategies and techniques for enhancing retention of patients with acute myocardial infarction and depression or social isolation. J Cardiopulm Rehabil (2003) 1.07
Comparability of telephone and In-person structured clinical interview for DSM-III-R (SCID) diagnoses. Assessment (1999) 0.98
A comparison of mail and telephone interview strategies for mental health surveys. Can J Psychiatry (1993) 0.90
Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale. Contemp Clin Trials (2006) 0.88
Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. J Affect Disord (2002) 0.87
A comparison of drugs versus placebo for the treatment of dysthymia. Cochrane Database Syst Rev (2000) 0.86
Tracking procedures and attrition containment in a long-term follow-up of a community-based ADHD sample. J Child Psychol Psychiatry (1996) 0.85
Computerizing medication algorithms and decision support systems for major psychiatric disorders. J Psychiatr Pract (2000) 0.81
A computerized clinical decision support system as a means of implementing depression guidelines. Psychiatr Serv (2004) 0.81
Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Psychopharmacol Bull (1998) 0.79
Is telephone assessment a valid tool in rehabilitation research and practice? Disabil Rehabil (2003) 0.77
Obstacles to implementing research outcomes in community settings. Gerontologist (2003) 0.77
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA (2006) 6.26
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med (2006) 6.00
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Exercise treatment for depression: efficacy and dose response. Am J Prev Med (2005) 4.99
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry (2006) 3.90
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol (2008) 3.65
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry (2006) 2.90
Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry (2007) 2.84
Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry (2011) 2.58
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry (2008) 2.42
A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry (2006) 2.21
Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA (2010) 2.16
The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep (2007) 2.08
Evidence-based recommendations for the prescription of exercise for major depressive disorder. J Psychiatr Pract (2013) 2.04
Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry (2008) 1.92
Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract (2006) 1.89
The pattern of sensory processing abnormalities in autism. Autism (2006) 1.83
Gender differences in depression: findings from the STAR*D study. J Affect Disord (2005) 1.80
Effect of age at onset on the course of major depressive disorder. Am J Psychiatry (2007) 1.78
Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry (2007) 1.78
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv (2009) 1.77
Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry (2005) 1.70
Prospective trial of equine-assisted activities in autism spectrum disorder. Altern Ther Health Med (2011) 1.69
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry (2007) 1.67
Inverse association between physical inactivity and mental health in men and women. Med Sci Sports Exerc (2006) 1.66
Measurement-based care in psychiatric practice: a policy framework for implementation. J Clin Psychiatry (2011) 1.65
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry (2002) 1.65
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med (2004) 1.64
The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol (2006) 1.58
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry (2008) 1.57
Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry (2006) 1.57
Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry (2003) 1.56
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr (2009) 1.55
Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract (2006) 1.55
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry (2007) 1.53
Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord (2005) 1.49
The impact of nonclinical factors on care use for patients with depression: a STAR*D report. CNS Neurosci Ther (2009) 1.49
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology (2005) 1.47
Impaired delay and trace eyeblink conditioning performance in major depressive disorder. J Affect Disord (2005) 1.45
Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry (2007) 1.45
Effect of 11 September 2001 terrorist attacks in the USA on suicide in areas surrounding the crash sites. Br J Psychiatry (2010) 1.45
Sensory correlations in autism. Autism (2007) 1.44
The current crisis of confidence in antidepressants. J Clin Psychiatry (2011) 1.44
STAR*D: revising conventional wisdom. CNS Drugs (2009) 1.41
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res (2009) 1.40
Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry (2010) 1.38
Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry (2009) 1.38
Treatment-resistant depression. J Clin Psychiatry (2006) 1.37
Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry (2009) 1.35
Prevention of missing data in clinical research studies. Biol Psychiatry (2006) 1.32
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology (2008) 1.29
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry (2010) 1.29
A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry (2015) 1.28
Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med (2008) 1.28
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend (2008) 1.24
TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design. Clin Trials (2006) 1.23
What predicts attrition in second step medication treatments for depression?: a STAR*D Report. Int J Neuropsychopharmacol (2008) 1.23
Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry (2011) 1.23
A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry (2015) 1.23
Defining and measuring functional recovery from depression. CNS Drugs (2010) 1.21
The STAR*D study: treating depression in the real world. Cleve Clin J Med (2008) 1.20
Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Compr Psychiatry (2008) 1.20
Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial. Trials (2011) 1.19
Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med (2007) 1.19
Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res (2009) 1.18
Insomnia in patients with depression: a STAR*D report. CNS Spectr (2010) 1.18
Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry (2005) 1.17
What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry (2006) 1.16
The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. Sleep (2003) 1.14
Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol (2011) 1.14
Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry (2010) 1.13
Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. Psychiatr Serv (2006) 1.12
Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. J Affect Disord (2008) 1.12
Symptom clusters as predictors of late response to antidepressant treatment. J Clin Psychiatry (2005) 1.11
Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. J Psychiatr Res (2006) 1.11
Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol (2008) 1.11
Epidemiology of nonfatal deliberate self-harm in the United States as described in three medical databases. Suicide Life Threat Behav (2006) 1.10
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depress Anxiety (2009) 1.10
Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord (2009) 1.08
The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. Control Clin Trials (2002) 1.08
Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend (2009) 1.06
Income and attrition in the treatment of depression: a STAR*D report. Depress Anxiety (2009) 1.05
Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. J Affect Disord (2006) 1.05
Sulfhydryl-reactive metals in autism. J Toxicol Environ Health A (2007) 1.05